Kristine Johnson - AtriCure Independent Director
| ATRC Stock | USD 23.39 0.06 0.26% |
Director
Ms. B. Kristine Johnson is Independent Director of the AtriCure Inc. since March 2017. Ms. Johnson is President of Affinity Capital Management, a VC firm that invests primarily in seed and earlystage health care companies in the United States. She has held this position since 2000. Prior to joining Affinity Capital Management in 1999, Ms. Johnson was Senior Vice President and Chief Administrative Officer of Medtronic, Inc. During her seventeen years at Medtronic, she also served as President and General Manager of its vascular business and President and General Manager of its tachyarrhythmia management business. She currently serves on the Board of Directors of Piper Jaffray, a publiclyheld middle market investment bank and asset management firm. She also serves as the Chair of the Investment Advisory Board of the University of Minnesota Foundation and on the boards of several private entities. Her previous public board experience includes service on the Boards of Directors of Spectranetics Corporationrationration, which was acquired by Philips, ADC Telecommunications, which was acquired by Tyco Electronics, and Pentair since 2017.
| Age | 66 |
| Tenure | 7 years |
| Address | 7555 Innovation Way, Mason, OH, United States, 45040 |
| Phone | 513 755 4100 |
| Web | https://www.atricure.com |
AtriCure Management Efficiency
The company has return on total asset (ROA) of (0.0324) % which means that it has lost $0.0324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.06. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mike Donovan | Axogen Inc | 53 | |
| Mark Gold | Axogen Inc | 69 | |
| Sriram Venkataraman | AngioDynamics | 42 | |
| Cornelia LeMaitre | LeMaitre Vascular | 78 | |
| Lisa Colleran | Axogen Inc | 59 | |
| Lawrence Jasinski | LeMaitre Vascular | 60 | |
| Robert Rudelius | Axogen Inc | 62 | |
| Dirk Kuyper | CONMED | 61 | |
| James Russell | LeMaitre Vascular | 42 | |
| Charles Farkas | CONMED | 68 | |
| Roger Stebbing | ATRION | 76 | |
| Alan Levine | Axogen Inc | 50 | |
| Martha Aronson | CONMED | 53 | |
| Giovannella Deiure | LeMaitre Vascular | 49 | |
| John Workman | CONMED | 69 | |
| Steven Laporte | AngioDynamics | 66 | |
| Jo Golden | CONMED | 69 | |
| David Bronson | CONMED | 67 | |
| Preston Athey | ATRION | 68 | |
| Wesley Johnson | AngioDynamics | 59 | |
| Michael Thomas | LeMaitre Vascular | 68 | |
Management Performance
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0324 |
AtriCure Leadership Team
Elected by the shareholders, the AtriCure's board of directors comprises two types of representatives: AtriCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AtriCure. The board's role is to monitor AtriCure's management team and ensure that shareholders' interests are well served. AtriCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AtriCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Salvatore Privitera, CTO | ||
| Patricia Kennedy, Vice President General Manager - International | ||
| Deborah Yount, Chief Officer | ||
| JD CCEP, Chief Officer | ||
| CCEP CCEP, Chief Officer | ||
| Regina Groves, Independent Director | ||
| Scott Drake, Independent Director | ||
| Mark Collar, Independent Director | ||
| Valerie StorchWillhaus, Vice Communications | ||
| Michael Carrel, CEO and President and Director | ||
| Mark Lanning, Independent Director | ||
| Richard Johnston, Independent Chairman of the Board | ||
| Robert White, Independent Director | ||
| Sven Wehrwein, Independent Director | ||
| Angela CPA, Chief Officer | ||
| Elizabeth Krell, Independent Director | ||
| Andrew Lux, Sr. VP of Operations and Quality Assurance | ||
| Tonya SPHR, VP HR | ||
| Vinayak Doraiswamy, Chief Officer | ||
| Michael Hooven, Founder and Director | ||
| Karen Robards, Independent Director | ||
| Salvatore JD, Chief Officer | ||
| Justin Noznesky, Senior Vice President Marketing and Business Development | ||
| Douglas Seith, Chief Officer | ||
| Andrew Wade, CFO, Senior Vice President | ||
| Kristine Johnson, Independent Director | ||
| Amalio MD, Ex Officer |
AtriCure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AtriCure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.066 | ||||
| Return On Asset | -0.0324 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 48.37 M | ||||
| Shares Owned By Insiders | 3.07 % | ||||
| Shares Owned By Institutions | 96.93 % | ||||
| Number Of Shares Shorted | 3.25 M | ||||
| Price To Earning | 33.47 X |
AtriCure Investors Sentiment
The influence of AtriCure's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in AtriCure. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to AtriCure's public news can be used to forecast risks associated with an investment in AtriCure. The trend in average sentiment can be used to explain how an investor holding AtriCure can time the market purely based on public headlines and social activities around AtriCure. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
AtriCure's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for AtriCure's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average AtriCure's news discussions. The higher the estimated score, the more favorable is the investor's outlook on AtriCure.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AtriCure in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AtriCure's short interest history, or implied volatility extrapolated from AtriCure options trading.
Pair Trading with AtriCure
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AtriCure position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AtriCure will appreciate offsetting losses from the drop in the long position's value.Moving together with AtriCure Stock
| 0.67 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
Moving against AtriCure Stock
| 0.73 | GCTK | GlucoTrack | PairCorr |
| 0.47 | WST | West Pharmaceutical Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to AtriCure could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AtriCure when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AtriCure - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AtriCure to buy it.
The correlation of AtriCure is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AtriCure moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AtriCure moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AtriCure can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for AtriCure Stock analysis
When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is AtriCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.66) | Revenue Per Share 8.621 | Quarterly Revenue Growth 0.21 | Return On Assets (0.03) | Return On Equity (0.07) |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.